IMU.AX Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 08:10):

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia...

Stats
Dagens volum	17.07M
Gjennomsnittsvolum	15.87M
Markedsverdi	578.26M
EPS	$0 ( 2024-03-01 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.90
ATR14	$0 (0.00%)

Volum Korrelasjon

Lang: -0.12 (neutral)

Kort: -0.69 (moderate negative)

Signal:(45.931) Neutral

Imugene Ltd Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Imugene Ltd Korrelasjon - Valuta/Råvare

0.00
( neutral )

Imugene Ltd Økonomi

Annual	2023
Omsetning:	$11.78M
Bruttogevinst:	$9.57M (81.29 %)
EPS:	$-0.00600

FY	2023
Omsetning:	$11.78M
Bruttogevinst:	$9.57M (81.29 %)
EPS:	$-0.00600

FY	2022
Omsetning:	$12.97M
Bruttogevinst:	$10.56M (81.44 %)
EPS:	$-0.00670

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.00453

Financial Reports:

No articles found.

Imugene Ltd

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.